At the last check on Friday, InspireMD Inc.’s (NASDAQ:NSPR) stock was up $0.14, moving up 4.47 percent to $3.24. The average number of shares traded per day over the past five days has been 204,314 shares. 4 times new highs have been achieved over the past 5 days, with a -$0.02 fall in that time frame. In the last twenty days, the average volume was 76,534, while in the previous 50 days, it was 107,775.
Since last month, NSPR stock rose 5.49%. Shares of the company fell to $2.81 on 08/04/23, the lowest level in the past month. A 52-week high of $3.74 was reached on 07/13/23 after having rallying from a 52-week low of $0.81. Since the beginning of this year, NSPR’s stock price has risen by 276.80% or $2.33, and marked a new high 20 times. However, the stock has declined by -13.41% since its 52-week high.
NSPR stock investors should be aware that InspireMD Inc. (NSPR) stock had its last reported insider trading activity 98 days ago on May 12. Stuka Paul, the Director of the company, purchased of 175,000 shares for $1.63 on May 12. It resulted in a $285,722 investment by the insider. BERMAN MICHAEL added 122,497 shares at an average price of $1.63 on May 12. The insider now owns 122,497 shares following the transaction. On May 12, Director ROUBIN GARY S bought 61,249 shares at $1.63 apiece. The transaction was valued at $100,001.
Valuation Metrics
The stock’s beta is 1.01. Besides these, the trailing price-to-sales (P/S) ratio of 12.94, the price-to-book (PB) ratio of 1.95.
Financial Health
In the three months ended June 30, InspireMD Inc.’s quick ratio stood at 3.40, while its current ratio was 3.80, showing that the company is able to pay off its debt. On the profitability front, the trailing twelve-month gross margin is 26.70% percent. Based on annual data, NSPR earned $1.12 million in gross profit and brought in $5.17 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -107.70%. Return on equity (ROE) for the past 12 months was -94.30%.
According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. NSPR’s revenue rose 20.81% to $1.03 million during the quarter, while net income inched up to $1.49 million. While analysts expected InspireMD Inc. to report -$0.3 quarterly earnings, the actual figure was -$0.24 per share. During the quarter, the company generated -$5.26 million in EBITDA. The liabilities of InspireMD Inc. were 6.83 million at the end of its most recent quarter ended June 30, and its total debt was $1.39 million. The value of shareholders’ equity is $21.2 million.
Technical Picture
This quick technical analysis looks at InspireMD Inc.’s (NSPR) price momentum. With a historical volatility rate of 29.63%, the RSI 9-day stood at 55.05% on 17 August.
With respect to its five-day moving average, the current InspireMD Inc. price is down by -0.62% percent or -$0.02. At present, NSPR shares trade -2.74% below its 20-day simple moving average and +184.82% percent above its 100-day simple moving average. However, the stock is currently trading approximately +86.55% above its SMA50 and +183.56% above its SMA200.
Stochastic coefficient K was 58.76% and Stochastic coefficient D was 56.32%, while ATR was 0.22. Given the Stochastic reading of 64.41% for the 14-day period, the RSI (14) reading has been calculated as 56.32%.
Analyst Ratings
Rodman & Renshaw launched its rating on InspireMD Inc. (NASDAQ: NSPR) to a Buy in a note to investors on January 07, 2016. InspireMD Inc. (NSPR) has been rated Buy by analysts. According to 0 brokerage firms, NSPR is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate InspireMD Inc. stock as buy, with 2 recommending it as overweight.
With a median target price of $4.35, the current consensus forecast for the stock is $3.50 – $5.20. Based on these forecasts, analysts predict InspireMD Inc. (NSPR) will achieve an average price target of $4.35.
